ArticlemAbs

A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors.

Michael W Bishop et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.